Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Up 641.7% in February

Pasithea Therapeutics Corp. (NASDAQ:KTTA) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 26,700 shares, an increase of 641.7% from the January 31st total of 3,600 shares. Approximately 2.6% of the company’s stock are short sold. Based on an average daily trading volume, of 1,040,000 shares, the days-to-cover ratio is currently 0.0 days.

Pasithea Therapeutics Price Performance

KTTA stock opened at $1.22 on Friday. The firm has a 50 day simple moving average of $2.28 and a 200-day simple moving average of $3.40. Pasithea Therapeutics has a twelve month low of $1.12 and a twelve month high of $9.25.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.